KRAS and non-small cell lung carcinoma: Currently, several clinical trials have reached phase I (NCT05621525, NCT05480865, NCT05375084) to evaluate BBP-398 alone or in combination with KRASG12C inhibitor (sotorasib) and programmed death receptor-1 blocking antibody (nivolumab), assessing the safety, tolerability, pharmacokinetics, and initial anticancer activity in patients with advanced solid tumors and advanced NSCLC with KRAS mutations.